Adam Finn
| Use attributes for filter ! | |
| Gender | Male |
|---|---|
| Age | 65 |
| Books | Hot Topics in Infection and Immunity in Children IV |
| Date of birth | January 1,1959 |
| Interests | Paediatrics |
| Vaccines | |
| Education | University of Oxford |
| University of Cambridge | |
| University of London | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 1483455 |
Adam Finn Life story
Adam Hugh Roderick Finn is professor of paediatrics at the University of Bristol and head of the Bristol Children’s Vaccine Centre.
What you need to know about Covid as new variant rises
... That is a tactical decision, says Dr Adam Finn, professor of paediatrics at the University of Bristol...
Strep A schools may be given preventive antibiotics
... Adam Finn, professor of paediatrics at the University of Bristol, told BBC News the bar for treatment may now be low...
Covid vaccine ‘waning immunity': How worried should I be?
... Prof Adam Finn, from the University of Bristol and a government vaccine adviser, says: " We are seeing significant numbers of unvaccinated and vaccinated people coming into hospital...
Covid: Is the pace of the vaccine booster rollout too slow?
... Government adviser Prof Adam Finn, from the University of Bristol, explained: " The [booster] programme is much more complicated now than before...
Positive trial results for Valneva Covid vaccine
... Lead investigator Prof Adam Finn, of the University of Bristol, said the results, shared in a press release, were both " impressive and extremely encouraging"...
Coronavirus: scientists at the brand's 5G claims 'utter nonsense'
... It would also be impossible to transfer 5G of the virus, Adam Finn, professor of paediatrics at the University of Bristol, she adds...
Positive trial results for Valneva Covid vaccine
The Valneva Covid vaccine that the UK cancelled a 100m dose order for last month, works well at priming the immune system to fight coronavirus, phase three trial results suggest.
Blood results from volunteers who received the jab had high levels of neutralising antibodies against the pandemic virus.
It outperformed the AstraZeneca vaccine on this measure in.
Valneva is seeking regulatory approval for its jab, manufactured in Scotland.
It is an inactivated whole virus vaccine, meaning it contains a dead version of coronavirus that cannot cause disease. This is the same way that flu and polio vaccines are made.
French pharmaceutical company Valneva said the vaccine had a " neutralising antibody seroconversion rate above 95%" and there were no severe cases of Covid seen in The Trial despite variants, such as Delta, being in circulation.
Lead investigator Prof Adam Finn , of the University of Bristol, said the results, shared in a press release, were both " impressive and extremely encouraging".
" These results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic, " He Said .
Valneva hopes to initially get the jab approved for those aged between 18 and 55, based on the age range of people in The Trial .
The Company said it has begun the vaccine approval process with the UK's health regulator, and is preparing to submit a request with the European Medicines Agency.
Valneva said the UK government had served a notice to The Firm , over allegations of a breach of the agreement. The vaccine manufacturer " strenuously" denied any breach.
Source of news: bbc.com
